Research & Development
Sandoz unveils generic Glatopa 40 mg/ml three times-a-week for relapsing forms of multiple sclerosis
13 February 2018 -

Sandoz reported on Monday the availability of Glatopa (glatiramer acetate injection) in 40 mg/ml for the treatment of relapsing forms of multiple sclerosis (MS).

The company said Glatopa (glatiramer acetate injection) 40 mg/ml is US FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone (glatiramer acetate injection) 40 mg/ml three times-a-week therapy for relapsing forms of multiple sclerosis (MS).

According to the company Glatopa was developed under a collaboration agreement with Momenta Pharmaceuticals Inc and is produced in the US.

In conjunction, Glatopa 40 mg/ml, along with Glatopa 20 mg/ml, will offer patients a complete range of dosing options. Glatopa 20 mg/ml was made available in the US in June 2015. Patients can expect the same patient services for Glatopa 40 mg/ml as for Glatopa 20 mg/ml.

Additionally, Sandoz GlatopaCare will offer a USD0 co-pay support programme to qualified patients, personalized injection training as well as 24-hour access to nurses and a free Starter Kit, which includes the Glatopaject injection device designed to work with both Glatopa 20 mg/ml and 40 mg/ml prefilled syringes.

Headquartered in Holzkirchen, Greater Munich area, Germany, Sandoz is a generic pharmaceuticals and biosimilars company and a division of the Novartis.